Skip to main content
SpringerLink
Log in

Lung Cancer Immunotherapy: Programmatic Development, Progress, and Perspectives

  • Chapter
  • First Online:
Molecular Vaccines

  • 1150 Accesses

Abstract

This chapter describes a decade of experience with lung cancer vaccine development at a single institution. Elements of review include rationale, developmental strategy, scientific approach relative to historical perspective, and clinical circumstance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tarver, T.: Cancer facts & figures 2012. American Cancer Society (ACS). J. Consum. Health Internet 16, 366–367 (2012)

    Article  Google Scholar 

  2. Howlader, N., et al. (eds.): SEER cancer statistics review, 1975-2009 (Vintage 2009 populations), National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/, based on Nov 2011 SEER data submission, posted to the SEER web site, Apr 2012

  3. van Meerbeeck, J.P., Fennell, D.A., De Ruysscher, D.K.: Small-cell lung cancer. Lancet 378, 1741–1755 (2011). doi:10.1016/S0140-6736(11)60165-7

    Article  PubMed  Google Scholar 

  4. Goldstraw, P., et al.: Non-small-cell lung cancer. Lancet 378, 1727–1740 (2011). doi:10.1016/S0140-6736(10)62101-0

    Article  PubMed  Google Scholar 

  5. Dalgleish, A.G.: Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 29, 8501–8505 (2011). doi:10.1016/j.vaccine.2011.09.012

    Article  PubMed  Google Scholar 

  6. Perez, C.A., Santos, E.S., Raez, L.E.: Active immunotherapy for non-small-cell lung cancer: moving toward a reality. Expert Rev. Anticancer Ther. 11, 1599–1605 (2011). doi:10.1586/era.11.155

    Article  PubMed  CAS  Google Scholar 

  7. Kantoff, P.W., et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010). doi:10.1056/NEJMoa1001294

    Article  PubMed  CAS  Google Scholar 

  8. Disis, M.L.: Immune regulation of cancer. J. Clin. Oncol. 28, 4531–4538 (2010). doi:10.1200/JCO.2009.27.2146

    Article  PubMed  CAS  Google Scholar 

  9. Shepherd, F.A., Douillard, J.Y., Blumenschein Jr., G.R.: Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J. Thorac. Oncol. 6, 1763–1773 (2011). doi:10.1097/JTO.0b013e31822e28fc

    Article  PubMed  Google Scholar 

  10. Scott, A.M., Wolchok, J.D., Old, L.J.: Antibody therapy of cancer. Nat. Rev. Cancer 12, 278–287 (2012). doi:10.1038/nrc3236

    Article  PubMed  CAS  Google Scholar 

  11. Hirschowitz, E.A., Hiestand, D.M., Yannelli, J.R.: Vaccines for lung cancer. J. Thorac. Oncol. 1, 93–104 (2006)

    Article  PubMed  Google Scholar 

  12. Palucka, K., Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265–277 (2012). doi:10.1038/nrc3258

    Article  PubMed  CAS  Google Scholar 

  13. Cranmer, L.D., Trevor, K.T., Hersh, E.M.: Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol. Immunother. CII 53, 275–306 (2004). doi:10.1007/s00262-003-0432-5

    Article  Google Scholar 

  14. Keenan, B.P., Jaffee, E.M.: Whole cell vaccines – past progress and future strategies. Semin. Oncol. 39, 276–286 (2012). doi:10.1053/j.seminoncol.2012.02.007

    Article  PubMed  CAS  Google Scholar 

  15. Keilholz, U., et al.: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. 25, 97–138 (2002)

    Article  PubMed  Google Scholar 

  16. Wolchok, J.D., et al.: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420 (2009). doi:10.1158/1078-0432.CCR-09-1624

    Article  PubMed  CAS  Google Scholar 

  17. Disis, M.L.: Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol. Immunother. CII 60, 433–442 (2011). doi:10.1007/s00262-010-0960-8

    Article  Google Scholar 

  18. Moodie, Z., et al.: Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. CII 59, 1489–1501 (2010). doi:10.1007/s00262-010-0875-4

    Article  Google Scholar 

  19. Hirschowitz, E.A., et al.: Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol. 22, 2808–2815 (2004). doi:10.1200/JCO.2004.01.074

    Article  PubMed  Google Scholar 

  20. Hirschowitz, E.A., Foody, T., Hidalgo, G.E., Yannelli, J.R.: Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 57, 365–372 (2007). doi:10.1016/j.lungcan.2007.04.002

    Article  PubMed  Google Scholar 

  21. Hirschowitz, E.A., et al.: Pilot study of 1650-G: a simplified cellular vaccine for lung cancer. J. Thorac. Oncol. 6, 169–173 (2011). doi:10.1097/JTO.0b013e3181fb5c22

    Article  PubMed  Google Scholar 

  22. Emens, L.A., Jaffee, E.M.: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65, 8059–8064 (2005). doi:10.1158/0008-5472.CAN-05-1797

    Article  PubMed  CAS  Google Scholar 

  23. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Kroemer, G.: Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59–73 (2008). doi:10.1038/nri2216

    Article  PubMed  CAS  Google Scholar 

  24. Garnett, C.T., Schlom, J., Hodge, J.W.: Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin. Cancer Res. 14, 3536–3544 (2008). doi:10.1158/1078-0432.CCR-07-4025

    Article  PubMed  CAS  Google Scholar 

  25. Kodumudi, K.N., et al.: A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16, 4583–4594 (2010). doi:10.1158/1078-0432.CCR-10-0733

    Article  PubMed  CAS  Google Scholar 

  26. Kudrin, A., Hanna Jr., M.G.: Overview of the cancer vaccine field: are we moving forward? Hum. Vaccines Immunother. 8, 1135–1140 (2012)

    Article  CAS  Google Scholar 

  27. Parmiani, G., et al.: Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18, 226–232 (2007). doi:10.1093/annonc/mdl158

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Our program has been fortunate to have received support from our institution, our cancer center, philanthropists, and foundations and extramurally from state-supported initiatives and the National Institutes of Health.

Author information

Authors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Kentucky, Chandler Medical Center, Lexington, KY, USA

    Edward A. Hirschowitz MD & Terry H. Foody RN

  2. Lexington Veteran’s Administration Medical Center, Lexington, KY, USA

    Edward A. Hirschowitz MD

  3. Department of Microbiology, Immunology and Human Genetics, University of Kentucky, Lexington, KY, USA

    John R. Yannelli PhD

Authors
  1. Edward A. Hirschowitz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terry H. Foody RN
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John R. Yannelli PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward A. Hirschowitz MD .

Editor information

Editors and Affiliations

  1. Institute for Molecular Vaccines, Heidelberg, Germany

    Matthias Giese

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Wien

About this chapter

Cite this chapter

Hirschowitz, E.A., Foody, T.H., Yannelli, J.R. (2013). Lung Cancer Immunotherapy: Programmatic Development, Progress, and Perspectives. In: Giese, M. (eds) Molecular Vaccines. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1419-3_23

Download citation

Publish with us

Policies and ethics

Search

Navigation